Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks

The JAK inhibitor shows efficacy and safety when used in combination with topical corticosteroids, and showed superiority in a head-to-head comparison with dupilumab.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Allergy & Clinical Immunology News Source Type: news